Surgery lowers pressure to preserve remaining vision. Mechanism, disease stage, prior surgery and the ability to attend follow-up determine the balance of benefit and harm.
Terminology and draft status
Terminology review is not complete. No new WHO UMD entry verification is claimed for this copy; pending entries and limits are recorded in terminology.md.
01Choose the goal and timing
Glaucoma surgery aims to preserve remaining vision by lowering intraocular pressure (IOP); it cannot restore established optic-nerve damage. IOP is a modifiable treatment target and a surrogate: visual-field progression, vision, quality of life and treatment burden also matter. A plumbing analogy can explain drainage, but does not capture neural injury or guarantee a cure. No procedure is a universal solution. 1 5
Document glaucoma subtype, angle by gonioscopy, visual field, optic nerve/OCT, rate of progression, baseline and treated IOP, corneal factors, fellow-eye function, lens status, conjunctiva and prior operations. Include medication tolerance, adherence, patient preference and ability to attend follow-up. Surgery may be appropriate when medication/laser is unlikely to preserve sight; exhausting every drop is not a prerequisite. For advanced disease TAGS supports discussing primary trabeculectomy, rather than imposing a rigid last-resort ladder. 1 5
Set and reassess a target for each eye, accounting for damage, progression, remaining lifetime, starting pressure and treatment risk. An advanced eye may need a substantially lower pressure than a mildly affected eye. Neither <15 mmHg nor a single stage threshold is a universal prescription; progression despite reaching the current target requires reassessment. 1
02Understand the outflow pathway
Conventional outflow passes through trabecular meshwork, Schlemm’s canal and collector channels; unconventional outflow includes the uveoscleral pathway. Resistance is distributed, including the juxtacanalicular/inner-wall region and distal pathways. The original 80–95%/5–20% flow shares and fixed75% resistance estimate are teaching approximations, not patient constants. Johnstone’s mechanical/pulsatile model is supported by experimental observations; it does not establish the best operation. The original biographical/death statement lacks a verified source and remains an explicitly unverified lecture note. 18 19
03Compare initial SLT with drops in the studied population
LiGHT was a UK multicentre randomized trial in treatment-naïve open-angle glaucoma/ocular hypertension. At6years69.8% of initially SLT-treated eyes remained at target without drops or incisional surgery; progression was19.6% versus26.8% with initial drops. General health/glaucoma quality-of-life measures EQ-5D, GUI, GQL-15 did not differ significantly; GSS symptom scores favoured SLT. Crossover after3years and73% retention of the original randomized participants limit a simple pure-treatment comparison. SLT can reduce reliance on daily drops, but is not suitable for every glaucoma. Lifetime savings, superior24-hour stability and the original65% clinician-preference survey require separate evidence and are not established here. 4
A2025 LiGHT corrigendum is identified in the later165 source ledger, but its full corrected tables remain a source task. The quoted historical trial appraisal is not an independent new verification of the correction, a lifetime cost model or all24-hour pressure patterns. 4 21
04Distinguish tissue removal, bypass and device-specific safety
Trabectome ablates trabecular tissue electrosurgically; Kahook Dual Blade (KDB) excises a strip; GATT opens the trabecular wall by circumferential suture/catheter trabeculotomy. Bent-needle goniotomy (BANG) is mechanically different from cautery and should not be named interchangeably with BNC. The original25G description is technique-specific: the2026 BANG RCT used23G. Hyphema, pressure spikes and incomplete target attainment matter. Instrument simplicity does not prove KDB equivalence, less fibrosis or zero total cost. 12
iStent inject places two bypass stents; Hydrus is an8mm canal scaffold spanning about90°. They act on conventional outflow and depend on downstream function. Segmental drainage is a mechanistic rationale, not a measured guarantee that two stents find a functional collector. The pivotal trials compared device+phaco with phaco alone in selected mild/moderate POAG; they do not prove equivalence to trabeculectomy or superiority among all devices. 10 11
CyPass was a supraciliary/suprachoroidal implant recalled in2018 after a long-term endothelial-cell-loss signal. That device-specific result cannot be assigned to every angle implant. For any implant, examine position and corneal status; determine endothelial assessment from the device, findings and risk. A blanket annual schedule for all MIGS is unsupported here. Existing CyPass implants require device-specific specialist follow-up, not automatic removal. 16
05Read bleb surgery and tube evidence by population
XEN drains to the subconjunctival space, commonly by an ab-interno route; PreserFlo is placed ab externo. These are bleb-forming procedures (often called MIBS), not simply interchangeable with trabecular MIGS. MMC and subsequent wound-healing intervention are commonly used, with local/off-label considerations; needling is possible rather than inevitable. Scarring, hypotony, leak, infection and placement-related injury must be discussed. Trials suggest trade-offs in pressure reduction and interventions, not universal device superiority. 8 9
The527-patient MicroShunt/trabeculectomy trial was designed for noninferiority, contradicting the original claim that a mistaken superiority design explained FDA refusal. At2years success was50.6% versus64.4%, and mean IOP13.9 versus10.7mmHg. On27July2026 Glaukos reported completed enrollment in a different U.S.510(k) pivotal study in previously treated refractory POAG. This is manufacturer information, not FDA clearance. The review did not independently establish current U.S. marketing authorization; the claims 'FDA allows no do-overs' and permanent exclusion remain unsupported. 8 17
Trabeculectomy with antifibrotic treatment can achieve low pressures and remains a key option for advanced disease. Tubes are important with prior surgery, scarring or high filtration-failure risk. PTVT and TVT studied different surgical histories: compare populations before declaring a winner. Ahmed/Baerveldt evidence shows lower pressure with Baerveldt but more hypotony-related failure; it cannot be transferred to every tube design. No source verifies the original resident-versus-expert explanation dismissing Bascom Palmer results. Surgeon expertise matters but is not evidence that a trial result is invalid. 5 6 7 13
Deep sclerectomy and viscocanalostomy preserve different tissue barriers from trabeculectomy; postoperative goniopuncture may be part of treatment. The older Cochrane review included five small, methodologically limited trials: it did not establish deep-sclerectomy equivalence to trabeculectomy. Cyclophotocoagulation reduces aqueous production; technique and visual potential affect selection. Inflammation, hypotony, vision loss and retreatment remain relevant; it is neither restricted categorically to blind eyes nor interchangeable with every drainage procedure. 1 14
06Match lens status and secondary mechanisms
Phaco alone or phaco+trabecular MIGS can suit selected early/moderate open-angle disease with a modest pressure/medication goal. A very low target or advanced progression requires consideration of a stronger pressure-lowering strategy. Stand-alone MIGS also exists. Phaco versus combined or staged bleb surgery depends on lens need, target, inflammation and conjunctival risk; there is no universal6/12-month waiting rule or automatic3-fold failure estimate. 1 10 11
Rubeosis, angle neovascularization, high IOP and pain need urgent coordinated retinal/glaucoma care. Gonioscopy distinguishes open from synechially closed angle. Treat the ischemic retinal drive (PRP when feasible; anti-VEGF as a context-dependent adjunct) and pressure as related but separate goals. Anti-VEGF evidence suggests short-term benefit with low/very-low certainty and unclear durable benefit; it does not replace definitive ischemia/pressure treatment. Tube, trabeculectomy or cyclodestruction selection depends on inflammation, angle, visual potential, bleeding risk and prior surgery; 'tube always first' is unjustified. Uveitis and silicone-oil glaucoma likewise require mechanism-specific planning, not an almost-certain failure assumption or automatic iridotomy in every pseudophakic eye. 1 15
07Plan healing, drops and urgent access
Aftercare is part of surgery: assess IOP, vision, anterior-chamber depth, inflammation, wounds/bleb, implant position and cornea. Early low pressure requires identifying leak, overfiltration or other cause; high pressure requires identifying retained viscoelastic, hyphema, steroid response, obstruction or scarring. A shallow chamber, infection or vision deterioration needs prompt specialist assessment. Bleb massage, suture adjustment, needling and5-FU/MMC are selected interventions, not routine instructions for every patient. Risks include hypotony maculopathy, choroidal complications, tube exposure and late bleb infection. Follow-up remains individualized and long term. 1 6 8 9
The original4-3-2-1 weekly schedule must not be applied simultaneously to antibiotics, steroids, pilocarpine and NSAIDs. Drug choice, frequency and taper depend on operation, inflammation, IOP and surgeon instructions; the2026 BANG/GATT study itself stopped antibiotic after one week and tapered steroid separately. Pilocarpine has selected uses after angle procedures but no established 'iris-memory' mechanism; consider discomfort and contraindications. Viscoelastic assists surgical chamber control, but retention can raise IOP; it is not a universally essential reflux/hyphema prophylaxis or a substitute for a secure wound. 1 12
The operation lowers pressure to protect remaining sight; drops or further procedures may still be needed. Attend scheduled checks and follow the individually prescribed drops and restrictions on rubbing, lifting and water exposure; duration is operation-specific. Severe pain, increasing redness, discharge or sudden visual loss requires immediate contact with the surgical team/emergency eye service. Late infection can occur months or years after bleb surgery. Educational information does not replace examination or individualized treatment. 20
Before a Schlemm-canal procedure, confirm an accessible open angle with gonioscopy and assess the target, severity, prior surgery and ability to attend follow-up. After surgery, tailor anti-inflammatory treatment and review pressure, wound, chamber and device/bleb findings. A filtering bleb needs lifelong education about infection symptoms and urgent access; a nonoperative follow-up consensus interval is not the postoperative schedule or the early pressure check after laser. 22
08Compare results, costs and uncertainty
The original prices Trabectome$1200, KDB$400, PreserFlo$1500 and needle surgery≈$0 lack dated country-specific procurement sources. Total cost also includes facilities, staff, disposables, follow-up and reoperation. Low-resource suitability, including Syria, requires access, sterilization, training and rescue pathways; no technique is endorsed as a country's preferred choice. The original AGS project/government-payment narrative remains an unverified lecture claim. Registries and prediction models may inform selection, but association, reimbursement policy and validated clinical benefit are different questions. Label algorithmic prediction as a future perspective, not proven practice. 4 12
The German MIGS guidance is DOG/BVA S1 AWMF045-029(April2025), not S3. Its bibliographic record and erratum were checked, but detailed full text was not independently accessible. AAO2025 PPP was located with the same extraction limitation. Therefore no precise recommendation is attributed to those unseen texts. EGS6 full text was inspected; the study results below provide independent primary comparisons. IOP/medication outcomes are not automatically quality-of-life or sight-preservation benefits. Nonsignificant differences do not establish equivalence; subgroup, short follow-up, missing data and industry involvement affect confidence. 1 2 3
LiGHT,6y InitialSLT/drops; treatment-naïve OAG/OHT Progression19.6%/26.8%; trabeculectomy13/32eyes; no significant EQ-5D/GUI/GQL-15 difference. 73% original-participant retention; crossover; not all glaucoma. 4
TAGS,5y Primary trabeculectomy/medical treatment;453new advanced OAG patients IOP12.07/14.76mmHg; adjusted difference−2.56(95%CI−3.80 to−1.32). VFQ-25 difference1.01(−1.99 to4.00), p=0.51; better field preservation with surgery. Not proof of QoL superiority; treatment unmasked; advanced newly diagnosed population. 5
PTVT,5y Baerveldt350/trab+MMC;242eyes without prior incisional surgery Failure42%/35%, p=0.21; IOP13.4/13.0; medications2.2/1.3. Nonsignificant failure difference is not equivalence; differs from TVT. 6
TVT,5y Tube/trab+MMC; previous cataract surgery and/or failed trab Failure29.8%/46.9%, p=0.002. Not primary-surgery PTVT population; not a universal NVG rule. 7
MicroShunt,2y MicroShunt/trab+MMC;527POAG patients;3:1 noninferiority trial Success50.6%/64.4%, p=0.005; IOP13.9/10.7; medications0.9/0.4; hypotony30.9%/51.1%. Trial-specific success/hypotony definitions;2years; cannot infer FDA rationale. 8
XEN GPS,12mo XEN/trab;POAG subgroup130treated patients(88/42) Composite success61.4%/69.0%, p=0.394; trab IOP reduction2.8mmHg greater; interventions39.8%/76.2%. Subgroup,12months, industry involvement; not equivalence or universal safety superiority. 9
HORIZON,5y Phaco+Hydrus/phaco alone; selected mild/moderate POAG IOP≤18without medication49.5%/33.8%, p=0.003; medication-free66%/46%; mean medication0.5/0.9. 80%5-year follow-up; phaco comparator; not advanced disease or trab comparison. 10
iStent inject,2y Phaco+two stents/phaco;505eyes(387/118) ≥20%unmedicated diurnal IOP reduction75.8%/61.9%, p=0.005; reduction7.0/5.4mmHg. Surrogate outcome and selected phaco population; not proof of optic-nerve recovery. 11
BANG/GATT,24mo 22/23eyes in34patients; pseudophakic mild/moderate POAG IOP reduction16.0%/22.44%; medication-free2/11eyes; complete success4.5%/55.0%. Small; examiner unmasked; endpoint retention19/22 and17/23. Abstract qualified success11.4% versus body13.6% for BANG: unresolved reporting discrepancy; not a KDB trial. 12
Ahmed/Baerveldt,5y Pooled twoRCTs;514eyes with failed/high-risk trab IOP15.8/13.2; failure49%/37%, p=0.007; hypotony failure0.4%/4.5%. Device/population-specific trade-off; not evidence for every tube including Paul. 13
| Procedure/topic | Mechanism/cost context | Evidence and use | Monitoring/limits |
|---|---|---|---|
| SLT | Selected first-line option | LiGHT: no general QoL superiority;see symptoms/progression | Pressure spikes, angle and pigmentation |
| BNC/BANG (original25G) | Bent-needle technique;not zero total cost | Different from cautery/KDB;2026trial used23G | Hyphema, pressure spikes;equivalence unproved |
| iStent/Hydrus | Bypass/scaffold;Hydrus8mm/90° | Selected phaco populations;not a universal trab comparator | Device-specific corneal/position surveillance, no universal annual rule |
| PreserFlo/XEN | Subconjunctival bleb | MicroShunt trial was noninferiority, not failed superiority design | Scarring, hypotony, leak/infection;MMC/needling selected |
| Trabeculectomy | Potential for low pressure | No universal superiority;PTVT/TVT populations differ | Experience matters;unverified Bascom Palmer bias claim |
| Postoperative4-3-2-1 | Original weekly taper example | Not one schedule for antibiotics, steroids, pilocarpine and NSAIDs | Individual medication/duration and review |
| Pilocarpine | Selected postoperative angle use | No established iris-memory mechanism | Contraindications, discomfort and pressure response |
| OVD | Chamber control, possible reflux modulation | Not mandatory hyphema prophylaxis or a substitute for secure wound | Retained OVD can raise pressure |
What are the main learning points?
Surgery lowers pressure to preserve remaining vision. Mechanism, disease stage, prior surgery and the ability to attend follow-up determine the balance of benefit and harm.
When is assessment urgent?
After surgery, severe pain, increasing redness, discharge, a shallow chamber or sudden visual loss needs urgent contact with the surgical team. Late bleb infection is also an emergency.
References and access status
- 1EGS 6 (2025), professional guideline; full text inspected, pp.22–24,163–164,192–202.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 2DOG/BVA S1, AWMF045-029, April2025; bibliographic verification only; detailed full-text recommendations not independently retrieved. Erratum10.1007/s00347-025-02343-2.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 3AAO POAG PPP2025; official record verified; full-text recommendations not extracted.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 4LiGHT6-year RCT: initial SLT versus drops, treatment-naïve OAG/OHT.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 5TAGS5-year RCT: primary trabeculectomy versus medication, newly diagnosed advanced OAG.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 6PTVT5-year RCT: Baerveldt350 versus trabeculectomy+MMC, no previous incisional ocular surgery.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 7TVT5-year RCT: tube versus trabeculectomy, previous cataract surgery and/or failed filtration.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 8MicroShunt versus trabeculectomy, randomized noninferiority trial,2years.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 9XEN45 GPS POAG subgroup, randomized study12months,2025.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 10HORIZON randomized trial,5years: phaco+Hydrus versus phaco alone.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 11iStent inject pivotal RCT,2years: phaco+two stents versus phaco alone.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 12BANG versus GATT RCT,24months; published28September2026.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 13Ahmed versus Baerveldt pooled randomized5-year evidence.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 14Deep sclerectomy/viscocanalostomy versus trabeculectomy, Cochrane2014.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 15Anti-VEGF for neovascular glaucoma, Cochrane2023.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 16FDA CyPass recall, initiated28August2018; device-specific endothelial safety signal.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 17Glaukos27July2026: enrollment completed in new U.S. PreserFlo510(k) pivotal study; company statement, not clearance.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 18Aqueous outflow resistance, mechanistic review2019.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 19Johnstone outflow mechanics, experimental ex-vivo study2016; supports mechanism, not clinical superiority.
Historical004 source appraisal of1October2026 reused; scope is stated in the title and source dossier, not fresh full-source access.
- 20Immutable original export; MIGS/MIBS original; own table/video preserved
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 21LiGHT corrigendum2025,DOI10.1016/j.ophtha.2025.07.029
Historical165 record of located corrigendum reused; no inferred correction content or fresh full corrected tables.
- 22AAO. Glaucoma Summary Benchmarks for Preferred Practice Pattern Guidelines (December 2025), pp. 1–9.
Historical005 supplied benchmark PDF access6October2026 reused; current direct AAO request returned403 on16November2026. Not a new full-PDF/PPP appraisal; exact current operative pages and product/local protocols remain open.
Original lecture link
For patients
An operation can protect remaining sight by lowering pressure, but drops, checks and sometimes another procedure may still be needed.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
After surgery, severe pain, increasing redness, discharge, a shallow chamber or sudden visual loss needs urgent contact with the surgical team. Late bleb infection is also an emergency.
After surgery, severe pain, increasing redness, discharge, a shallow chamber or sudden visual loss needs urgent contact with the surgical team. Late bleb infection is also an emergency.